Alejandro Piris logo Academic Members logo

Alejandro Piris

Chief Scientific Officer, Vall d'Hebron Institute of Oncology, VHIO (Spain)


Chief Scientific Officer and Head of the Scientific Management Area at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona (Spain). My tasks at VHIO include: Scientific support to the Director and strategic decisions on research activities; writing, coordination and management of scientific proposals; monitoring and evaluation of existing scientific & institutional programs; identification of competitive research funds/ opportunities and international research consortia. Member of VHIO’s Internal Scientific Committee and evaluator of national/ international research Calls. Master’s in management of R, D & I in Health Sciences. Previously worked in Translational Cancer Drugs Pharma (biotech company) and Mensor (Research Department). In terms of academic training: I graduated in Veterinary Science (Complutense University of Madrid) and hold a PhD cum laude in Biochemistry and Molecular Biology (Pasteur Institute and Denis Diderot University, Paris). I have also completed a post-doctoral stay (Juan de la Cierva Program) at the National Center for Biotechnology (Madrid), focused on the design of new viral vaccines.

Main 5 articles co-authored in last 5 years (2018-2022), include: (1) RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer. Nat Med. 2022 Oct;28(10):2162-2170; (2) ERANET JTC 2011: Submission and Activation of an International Academic
Translational Project in Advanced Breast Cancer. Experience From the ET-FES Study. Monti M et al. Front Med (Lausanne). 2022 Jan 13;8:817678; (3) Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Tamborero D et al. Nat Med. 2020 Jul;26(7):992-994; (4) Caring for patients with cancer in the COVID-19 era. Van de Haar J et al. Nat Med. 2020 May;26(5):665-671; (5) New clinical trial designs in the era of precision medicine. Garralda E et al. Mol Oncol. 2019 Mar;13(3):549-557.

My personal interest is cancer research at all levels, but with special focus in Personalized Medicine and Scientific Management.


Why WIN

WIN is a very nice, challenging and unique example of international collaborative research, and has succeeded in allying academic and non-academic stakeholders to jointly develop pioneering proposals in Personalized Oncology. WIN completely converges with VHIO’s Vision of international collaborative research.

Alejandro Piris logo

Alejandro Piris

Chief Scientific Officer, Vall d'Hebron Institute of Oncology, VHIO (Spain)


Academic Members logo

Chief Scientific Officer and Head of the Scientific Management Area at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona (Spain). My tasks at VHIO include: Scientific support to the Director and strategic decisions on research activities; writing, coordination and management of scientific proposals; monitoring and evaluation of existing scientific & institutional programs; identification of competitive research funds/ opportunities and international research consortia. Member of VHIO’s Internal Scientific Committee and evaluator of national/ international research Calls. Master’s in management of R, D & I in Health Sciences. Previously worked in Translational Cancer Drugs Pharma (biotech company) and Mensor (Research Department). In terms of academic training: I graduated in Veterinary Science (Complutense University of Madrid) and hold a PhD cum laude in Biochemistry and Molecular Biology (Pasteur Institute and Denis Diderot University, Paris). I have also completed a post-doctoral stay (Juan de la Cierva Program) at the National Center for Biotechnology (Madrid), focused on the design of new viral vaccines.

Main 5 articles co-authored in last 5 years (2018-2022), include: (1) RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer. Nat Med. 2022 Oct;28(10):2162-2170; (2) ERANET JTC 2011: Submission and Activation of an International Academic
Translational Project in Advanced Breast Cancer. Experience From the ET-FES Study. Monti M et al. Front Med (Lausanne). 2022 Jan 13;8:817678; (3) Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Tamborero D et al. Nat Med. 2020 Jul;26(7):992-994; (4) Caring for patients with cancer in the COVID-19 era. Van de Haar J et al. Nat Med. 2020 May;26(5):665-671; (5) New clinical trial designs in the era of precision medicine. Garralda E et al. Mol Oncol. 2019 Mar;13(3):549-557.

My personal interest is cancer research at all levels, but with special focus in Personalized Medicine and Scientific Management.


Why WIN

WIN is a very nice, challenging and unique example of international collaborative research, and has succeeded in allying academic and non-academic stakeholders to jointly develop pioneering proposals in Personalized Oncology. WIN completely converges with VHIO’s Vision of international collaborative research.